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Osteoarthritis (OA) is a progressive degenerative disease of the 
joint; its symptoms include synovial inflammation, cartilage loss, 
torn ligaments, osteophyte formation, and joint space narrowing (1). 
All of these lead to increased pain sensation, stiffness of the joint, 
lameness, and often a severely decreased quality of life. While the 
exact cause of OA is not known, it is associated with both environ-
mental factors, such as obesity, age, and damage of the joint, as well 
as genetic factors, including dysplasia (2).
Regenerative medicine provides novel tools to repair dam-
aged cartilage in joints as demonstrated by a plethora of research 
articles and clinical trials focusing on the role of chondrocytes 
and mesenchymal stem cells (MSCs) in treating OA (3). As MSCs 
are multi potent stromal cells that lack specific surface markers, 
the International Society for Cellular Therapy has declared that 
MSCs must meet 3 criteria, they should: i) grow as adherent cells; 
ii) express CD44, CD90, and CD105, while lacking endothelial and 
hematopoietic markers CD45, CD34, CD14 or CD11b, CD79a or 
CD19, as well as HLA-DR; and iii) be able to differentiate into chon-
drocytes, adipocytes, and osteocytes (4).
Most studies have analyzed the function of bone marrow MSCs 
(BM-MSCs) and adipose tissue-derived MSCs (AT-MSCs) (5). While 
AT-MSCs are similar to BM-MSCs in terms of their usefulness in 
regenerative medicine, they have an important advantage over 
BM-MSCs, namely, that they can be isolated in larger numbers 
using a minimally invasive procedure (5). As AT-MSCs are non-
immunogenic and have a potent immunosuppressive activity, they 
can be used safely in allogeneic or even xenogeneic transplantation 
in OA and other models without the need for immunosuppressive 
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A b s t r a c t
Visceral adipose tissue (AT) obtained from surgical waste during routine ovariectomies was used as a source for isolating 
canine mesenchymal stem cells (MSCs). As determined by cytofluorimetry, passage 2 cells expressed MSC markers CD44 and 
CD90 and were negative for lineage-specific markers CD34 and CD45. The cells differentiated toward osteogenic, adipogenic, 
and chondrogenic directions. With therapeutic aims, 30 dogs (39 joints) suffering from elbow dysplasia (ED) and osteoarthritis 
(OA) were intra-articularly transplanted with allogeneic MSCs suspended in 0.5% hyaluronic acid (HA). A highly significant 
improvement was achieved without any medication as demonstrated by the degree of lameness during the follow-up period 
of 1 y. Control arthroscopy of 1 transplanted dog indicated that the cartilage had regenerated. Histological analysis of the 
cartilage biopsy confirmed that the regenerated cartilage was of hyaline type. These results demonstrate that transplantation of 
allogeneic adipose tissue-derived mesenchymal stem cells (AT-MSCs) is a novel, noninvasive, and highly effective therapeutic 
tool in treating canine elbow dysplasia.
Résumé
Du tissu adipeux viscéral (TA) obtenu de résidus chirurgicaux lors d’ovariectomies de routine a été utilisé comme source pour isoler des cellules 
souches mésenchymateuses canines (CSMs). Tel que déterminé par cytofluorométrie, les cellules du 2e passage exprimaient les marqueurs 
de CSM CD44 et CD90, et étaient négatives pour les marqueurs spécifiques de lignée CD34 et CD45. Les cellules se sont différenciées 
dans des directions ostéogéniques, adipogéniques, et chondrogéniques. À des fins thérapeutiques, 30 chiens (39 articulations) souffrant de 
dysplasie du coude (DC) et d’ostéoarthrite (OA) ont reçu une transplantation intra articulaire de CSMs allogéniques en suspension dans 
0,5 % d’acide hyaluronique (AH). Une amélioration hautement significative a été obtenue sans aucune médication tel que démontré par le 
degré de boiterie durant la période de suivi de 1 an. Une arthroscopie de contrôle de un des chiens ayant reçu une transplantation montrait 
que le cartilage s’était régénéré. L’analyse histologique de la biopsie du cartilage a confirmé que le cartilage régénéré était de type hyalin. 
Ces résultats démontrent que la transplantation de cellules souches mésenchymateuses dérivées de tissu adipeux allogène est un outil 
thérapeutique novateur, non-invasif, et très efficace pour traiter la dysplasie du coude chez le chien.
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medications (6,7). To enhance their effect, improve MSC survival, 
and ensure the prolonged presence of MSCs in a harsh microenvi-
ronment, MSCs can be combined with traditional treatments such 
as injecting hyaluronic acid (HA) (8,9).
The objective of this study was to evaluate the long-term effects 
of administering MSCs dispersed in an HA solution on regeneration 
of osteoarthritic elbow joints in dogs. Allogeneic AT-MSCs were 
isolated from surgical waste obtained from the spaying of female 
mixed-breed dogs and were characterized by marker analysis and 
differentiation. The cells were suspended in HA and injected into 
joints of dogs suffering from elbow dysplasia with OA. The treat-
ment efficacy was assessed using questionnaires completed by the 
dog owners based on changes in the dogs’ lameness. Transplantation 
of MSCs resulted in highly significant long-term improvement (over 
a 1-year period) in the condition of the involved animals.
This study was approved by the National Scientific Ethical 
Committee of the National Food Chain Safety Office. All the dog 
owners signed an informed consent authorizing treatment and 
were informed of the possible risks of joint injections and potential 
complications of the procedure.
Visceral adipose tissue (AT) was collected by a veterinarian from 
13 healthy, small, mixed-breed dogs that underwent all routine vac-
cinations and were regularly surveyed by veterinarians. Adipose 
tissue was digested with 0.1% collagenase (Sigma Aldrich, St. Louis, 
Missouri, USA) in Hank’s buffer for 30 min at 37°C. The resulting 
stromal vascular fraction (SVF) was plated at 104/cm2 in DMEM/
F12 containing 10% fetal calf serum (FCS), 2 mM glutamine, and 
50 U/mL penicillin and streptomycin (complete medium) (all 
from Thermo Fisher Scientific, Waltham, Massachusetts, USA). 
Cultures were grown up to 80% confluency, diluted twice to reach 
stage passage 2 (P2), and stored in liquid nitrogen until further 
usage.
Passage 2 (P2) cells from 8 donors were analyzed for surface 
markers by cytofluorimetry (FACSCalibur; BD Biosciences, San José, 
California, USA) using the following antibodies: fluorescein isothio-
cyanate (FITC)-conjugated rat anti-mouse/human CD44 (BioLegend, 
San Diego, California, USA); Phycoerythrin (PE)-conjugated rat 
anti-canine CD90 (eBioscience, San Diego, California, USA); 
FITC-conjugated rat anti-canine CD45 (eBioscience); and FITC-
conjugated mouse anti-canine CD34 (R&D Systems, Minneapolis, 
Minnesota, USA). The data were evaluated using CellQuest software 
(BD Biosciences).
The differentiation capacity of P2 cells was tested as follows. The 
cells were fixed in 8% formaldehyde in phosphate-buffered saline 
(PBS) for 15 min after culturing cells in osteogenic differentiation 
medium (10 mM b-glycerophosphate, 50 mg/mL L-ascorbic acid 
2-phosphate, and 10 nM dexamethasone, all from Sigma Aldrich) for 
21 d (10) or adipogenic differentiation medium (15% rabbit serum, 
2 mM glutamine, and 50 U/mL penicillin and streptomycin contain-
ing DMEM/F12) for 4 d (11). The cultures were then stained with 1% 
Alizarin Red S for 45 min or AdipoRed (Lonza, Basel, Switzerland) 
for 15 min and analyzed with an Olympus CKX41 microscope at 
2003 magnification or a fluorescent Olympus microscope (Olympus 
IX81) at 1003 magnification, respectively. Photos were taken with 
an Olympus C-5060 digital camera from 5 non-overlapping regions 
for osteogenic and adipogenic differentiation.
Chondrogenic differentiation was induced according to 
Bosnakovski et al (12) in 3-dimensional pellet culture without any 
growth factor for 21 d. Fifteen chondrogenic pellets were collected 
and digested with 0.3% collagenase (Sigma Aldrich) in Hank’s buf-
fer containing 2 U/mL RNase inhibitor (RNasin Promega, Madison, 
Wisconsin, USA) for 30 min at 37°C in a water bath. Total ribo-
nucleic acid (RNA) was isolated from the pellet cultures and from 
non-induced cells as control using a Perfect Pure RNA Kit (5Prime, 
Gaithersburg, Maryland, USA) according to the manufacturer’s 
instructions. A RevertAid H Minus First-Strand cDNA Synthesis 
Kit (Thermo Fisher Scientific) was used to obtain complementary 
deoxyribonucleic acid (cDNA) from 94 ng of total RNA/reaction. 
Quantitative real-time polymerase chain reaction (qPCR) was carried 
out using an AccuPower 2X Greenstar qPCR Master Mix (Bioneer, 
Daejeon, Republic of Korea) in a RotoGene3000 instrument (Qiagen, 
Hilden, Germany).
Relative quantification of gene expression was done by com-
paring threshold values. All results were normalized to Gapdh 
(Gapdh: forward: TGGCAAAGTGGATATTGTCG reverse: AGATG 
GACTTCCCGTTGATG) and qPCR primers (Sox9: forward: ACGAC 
TACACTGACCACCAGAAC reverse: GTAGGTGAAGGTGGAGTAG 
AGGC, Aggrecan: forward: TTGCACTCAGGAGAGGAGAC reverse: 
CCACGCAGGTGGCTCCATTC) were used as in Lee et al (13) and 
Zang et al (14), with slight modifications.
Osteogenic, adipogenic, and chondrogenic differentiation assays 
were carried out on MSC cultures derived from 3 donors for 
osteogenic, 1 donor for adipogenic and 1 donor for chondogenic 
differentiation.
Preparation of AT-MSCs for therapy
Passage 2 AT-MSCs from 2 different adipose tissue donors were 
thawed, cultured for 3 d, mixed, and suspended in 0.5% sodium hyal-
uronate (TRB Chemedica International S.A. Geneva, Switzerland). 
Adipose tissue-derived MSCs (12 3 106 6 3.2 3 106 cells/injection) 
were transported to the veterinarian clinics in syringes. In total, 
6 different MSC cultures derived from 6 donors were used for 
transplantation.
Patient selection
Thirty-nine elbow joints from 30 dogs were included in the study. 
The inclusion criteria were recurrent lameness and pain attributed to 
OA after conventional treatment of dogs suffering from elbow dys-
plasia and cartilage degeneration (nonsteroidal anti-inflammatory 
drugs, intra-articular injection of hyaluronic acid, arthroscopy, or 
traditional surgery). Five dogs with osteoarthritic elbows were 
excluded as they were receiving pain relief medication for additional 
hip dysplasia or were undergoing analgesic treatment for spinal disc 
herniation. During this study, 6 dogs with elbow dysplasia died 
due to diseases unrelated to transplantation. Anti-inflammatory 
drugs (carprofen or meloxicam) were administered 10 d before 
transplantation.
The health status of the treated dogs was evaluated by the owners 
using a questionnaire modified from Black et al (15), as well as a sur-
vey by the veterinarians. The veterinarians taking part in the survey 
also collected data regularly from the owners and the results at 6, 9, 
and 12 mo were used to assess the effectiveness of stem cell treatment.
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Figure 1. Characterization of adipose tissue-derived mesenchymal stem cells (AT-MSCs). A — The presence of CD341, CD451, CD441, and CD901 cells 
was analyzed in isolated stromal vascular fraction (SVF) (top row) and cultured AT-MSC (bottom row) with flow cytometer. Grey histograms represent 
control samples without any antibody and black-lined histograms show fluorochrome-conjugated, antibody-stained samples. Percentages indicate the 
proportion of positive cells to the analyzed surface marker in the cell population. B — Osteogenic differentiation. Extracellular calcium was stained 
with Alizarin Red S solution. Representative figure shows matrix mineralization in an induced passage 2 cell culture. Original magnification: 2003, 
scale bar = 500 mm. C — Adipogenic differentiation. Accumulated lipid droplets were stained with AdipoRed (red) and nuclei were dyed with Hoechst 
33342 (blue). Original magnification: 1003, scale bar 100 mm. D — Chondrogenic differentiation. Chondrogenic induction was carried out in micromass 
culture and quantitative polymerase chain reaction (qPCR) was conducted for mRNA expression of Sox9 and aggrecan. Cells on day 0 of micromass 
induction served as control. Results are expressed as mean 6 standard deviation.
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Arthroscopic record samples were taken from 1 dog before cell 
injection and 12 mo after transplantation when the biopsy sample 
was also taken. As the dog’s diagnosis was fissured medial coronoid 
process, a subtotal coronoidectomy was carried out and the torn part 
was removed. Images were copied from the video, which referred 
to the same site of the ulna. As the original video was taken at low 
resolution, we were not able to present better quality images. The 
biopsy specimen was taken from the regenerated area of the cartilage 
of 1 dog during arthroscopic survey. After fixation in 10% neutral 
buffered formalin for 24 h at room temperature, tissue samples were 
dehydrated in a series of ethanol and xylene baths and embedded 
in paraffin wax. Sections (3 to 4 mm) were stained with hematoxylin 
and eosin or Safranin O. The slides were analyzed using an Olympus 
BX53 light microscope and images were taken with an Olympus 
SC100 digital camera using the Olympus cellSense software. Data 
were calculated as mean 6 standard error of mean (SEM) and groups 
were compared using the nonparametric Wilcoxon test.
Cell surface markers of the initial SVF and cultured MSCs were 
analyzed. The stromal vascular fraction (SVF) contained cells with 
lineage-specific markers (66% CD341 hematopoietic progenitor and 
Figure 2. Therapeutic effect of adipose tissue-derived mesenchymal stem cells (AT-MSCs). A — Lameness was rated by the owners using a question-
naire modified from Black et al (15). Results were substantiated by the nonparametric Wilcoxon test. *P , 0.001, N = 39. B — Images were excised 
from videos taken during arthroscopic surgery 3 wk before MSC injection (left image) and control arthroscopy 1 y after transplantation (right image). 
Images represent the same area of the joint. C — Images of tissue samples at 2003 magnification, stained with hematoxylin and eosin (H&E, upper 
row) and Safranin O (lower row), obtained from the regenerated cartilage (left column), a healthy meniscus cartilage (middle), and healthy cartilage 
(right column). Scale bar = 50 mm.
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endothelial cells and 12% CD451 leucocytes) and cells with MSC 
markers (48% CD44 and 78% CD90). After culturing, the contaminat-
ing cell lineages disappeared and the resulting homogenous CD441 
and CD901 cell population was referred to as AT-MSCs (Figure 1A). 
Passage 2 AT-MSCs were analyzed for differentiation capacity. 
The results showed that AT-MSCs differentiated into osteoblasts 
(Figure 1B) and adipocytes (Figure 1C), as verified by Alizarin Red 
for extracellular calcium and AdipoRed for lipid droplet staining. 
Elevation of aggrecan and Sox9 messenger RNA (mRNA) expres-
sion was detected when chondrocyte differentiation was induced 
(Figure 1D).
Thirty dogs (39 joints) suffering from elbow dysplasia resulting in 
OA and cartilage degeneration were treated with AT-MSCs and fol-
lowed for 1 y by veterinarians and the owners. Based on the owners’ 
evaluations, AT-MSCs had significant effect (31 cases out of 39) on 
the dogs’ lameness during walking (Figure 2A) without any further 
medication for at least a 1-year period. Three further joints from the 
39 showed stable improvement in lameness, with only occasional 
application of painkillers required.
Comparison of arthroscopic images taken before and after trans-
plantation showed regenerated cartilage islets in the MSC-treated 
joint (Figure 2B). Analysis of hematoxylin-eosin stained slides 
revealed that the repaired tissue was hyaline-like cartilage with 
fibrous elements (upper left, Figure 2C) compared to hyaline car-
tilage from a healthy joint (upper right, Figure 2C) and it was 
morphologically very different than fibrocartilage obtained from a 
healthy dog, which is typically found in the meniscus (upper middle, 
Figure 2C). The regenerated cartilage and healthy hyaline cartilage 
had lower cell density and less fibrous elements than fibrocartilage 
(Figure 2C). Moreover, Safranin O staining indicated higher glycos-
aminoglycan (GAG) content in the regenerated cartilage (lower left, 
Figure 2C) and healthy hyaline cartilage (lower right, Figure 2C) 
compared to fibrocartilage (lower middle, Figure 2C).
Damage from osteoarthritis and cartilage does not heal spon-
taneously due to poor vascularization and high density synovial 
fluid. There is therefore a great need for novel therapies to enhance 
formation of proper cartilage as well as to inhibit and cure OA. 
This is especially the case for elbow dysplasia, for which there are 
far fewer surgical solutions than for hip dysplasia. Recent develop-
ments include the local transplantation of MSCs into the articular 
cavity. This study shows that visceral adipose tissue is an excellent 
source of canine MSCs. After isolation, MSCs showed the expected 
characteristics, including the expression of cell surface markers, 
CD90 and CD44. Moreover, they were free of the lineage-specific 
markers CD45 and CD34 and retained their differentiation capabil-
ity, since they differentiated toward osteogenic, adipogenic, and 
chondrogenic directions.
Intra-articular injection of AT-MSCs resulted in highly signifi-
cant and sustained improvement in the condition of the patients. 
Lameness was ameliorated after 3 mo of treatment (data not shown) 
without any further medication and this improvement persisted at 
least during the 1-year survey. To our knowledge, this is the longest 
survey carried out with the largest patient population in the litera-
ture. It is worth mentioning that several additional dogs suffering 
from osteoarthritis in joints other than the elbow have also been 
treated with MSCs with encouraging results. The dogs’ conditions 
improved after MSC transplantation in 3 out of 4 hip cases, 2 out 
of 2 shoulder cases, 3 out of 3 knee cases, and 3 out of 3 hock joints 
(data not shown). Side effects were rare, with swelling for several 
days in 2 of 39 treated joints. Comparison of surgical and control 
arthroscopy confirmed newly regenerated cartilage after treatment. 
Although fibrocartilage tissue is formed during spontaneous repair 
of damaged hyaline cartilage, our results clearly indicate that MSC 
transplantation induces hyaline-like cartilage formation, which is 
more adequate for proper joint function. Our results strongly indi-
cate that the significant improvement in lameness is attributable to 
the formation of long-lasting (sustained), hyaline-like cartilage repair 
tissue due to AT-MSC transplantation.
A c k n o w l e d g m e n t s
The authors thank Karolina Korom and Marietta Görög for 
collecting information from dogs’ owners and liaising with the 
veterinarians involved in the program. We are grateful to the vet-
erinarians, Drs. Ottó Sebo´´ (Small Animal Clinic, Makó), Péter Pál 
Muka (Profivet Veterinary Surgery Center and Animal Hospital, 
Göd), Péter Makai (MiniVet Small Animal Clinic, Budapest), György 
Pelle (Teaching Animal Hospital, Nyíregyháza), and András Bánfi 
(PrimaVet Small Animal Clinic, Budapest), for surgery, trans-
plantation, and supervision of the dogs. The authors also thank 
Ákos Hornung for helpful advice about statistical evaluation 
and Mrs. Andrea Gercsó and Katalin Kovács for their excellent 
assistance. This work was supported by grants, GINOP-2.3.2-15-
2016-00020 and GINOP-221-5-2016-00007.
Re f e r e n c e s
 1. Man GS, Mologhianu G. Osteoarthritis pathogenesis — A com-
plex process that involves the entire joint. J Med Life 2014;7:37–41.
 2. Poulet B, Staines KA. New developments in osteoarthritis and 
cartilage biology. Curr Opin Pharmacol 2016;28:8–13.
 3. Zhang W, Ouyang H, Dass CR, Xu J. Current research on phar-
macologic and regenerative therapies for osteoarthritis. Bone 
Res 2016;4:15040.
 4. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria 
for defining multipotent mesenchymal stromal cells. The 
International Society for Cellular Therapy position statement. 
Cytotherapy 2006;8:315–317.
 5. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. 
Same or not the same? Comparison of adipose tissue-derived 
versus bone marrow-derived mesenchymal stem and stromal 
cells. Stem Cells Dev 2012;21:2724–2752.
 6. Gutiérrez-Fernández M, Rodríguez-Frutos B, Ramos-Cejudo J, 
et al. Comparison between xenogeneic and allogeneic adipose 
mesenchymal stem cells in the treatment of acute cerebral infarct: 
Proof of concept in rats. J Transl Med 2015;13:4–13.
 7. Tsai S-Y, Huang Y-C, Chueh L-L, Yeh L-S, Lin C-S. Intra-articular 
transplantation of porcine adipose-derived stem cells for 
the treatment of canine osteoarthritis: A pilot study. World J 
Transplant 2014;4:196–205.
 8. Chen PY, Huang LLH, Hsieh HJ. Hyaluronan preserves the 
proliferation and differentiation potentials of long-term cultured 
78 The Canadian Journal of Veterinary Research 2000;64:0–00
murine adipose-derived stromal cells. Biochem Biophys Res 
Commun 2007;360:1–6.
 9. Altman AM, Abdul Khalek FJ, Seidensticker M, et al. Human 
tissue-resident stem cells combined with hyaluronic acid gel 
provide fibrovascular-integrated soft-tissue augmentation in 
a murine photoaged skin model. Plast Reconstr Surg 2010;125: 
63–73.
10. Vieira NM, Brandalise V, Zucconi E, Secco M, Strauss BE, Zatz M. 
Isolation, characterization, and differentiation potential of canine 
adipose-derived stem cells. Cell Transplant 2010;19:279–289.
11. Diascro DD, Vogel RL, Johnson TE, et al. High fatty acid content 
in rabbit serum is responsible for the differentiation of osteo-
blasts into adipocyte-like cells. J Bone Miner Res 1998;13:96–106.
12. Bosnakovski D, Mizuno M, Kim G, et al. Chondrogenic differen-
tiation of bovine bone marrow mesenchymal stem cells in pellet 
cultural system. Exp Hematol 2004;32:502–509.
13. Lee KS, Cha SH, Kang HW, et al. Effects of serial passage on 
the characteristics and chondrogenic differentiation of canine 
umbilical cord matrix derived mesenchymal stem cells. Asian-
Australas J Anim Sci 2013;26:588–595.
14. Zhang N, Dietrich MA, Lopez MJ. Canine intra-articular multi-
potent stromal cells (MSC) from adipose tissue have the highest 
in vitro expansion rates, multipotentiality, and MSC immuno-
phenotypes. Vet Surg 2013;42:137–146.
15. Black LL, Gaynor J, Gahring D, et al. Effect of adipose-derived 
mesenchymal stem and regenerative cells on lameness in dogs 
with chronic osteoarthritis of the coxofemoral joints: A random-
ized, double-blinded, multicenter, controlled trial. Vet Ther 2007; 
8:272–284.
